Dorthe Lisbeth Jeppesen

Dorthe Lisbeth Jeppesen

Auto-generated profile, based on publicly available information

Dorthe Lisbeth Jeppesen

Department of Clinical Medicine, University of Copenhagen , Blegdamsvej 3B, 2200 Copenhagen

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2015 in Contemporary Clinical Trials
Verified
Journal Article
Open access
LTLisbeth Marianne Thøstesen
Lisbeth Marianne Thøstesen
TNThomas Nørrelykke Nissen
Thomas Nørrelykke Nissen
JKJesper Kjærgaard
Jesper Kjærgaard
GPGitte Thybo Pihl
Gitte Thybo Pihl
NBNina Marie Birk
Nina Marie Birk
LSLone Graff Stensballe
Lone Graff Stensballe
Studies from low-income countries report positive non-specific effects of early Bacillus Calmette-Guérin (BCG) immunisation on childhood health and survival. Neonatal immunisation with BCG may prime the immune system and offer partial protection against other infectious and possibly allergic diseases. The potential clinical value of these non-specific effects has not yet been examined in a large randomised trial in high-income countries. The Danish Calmette Study is a multicentre randomised clinical trial conducted between October 2012 and November 2015. Within the first 7 days of life, infants were randomly assigned to intra-dermal vaccination with BCG or no intervention. At 3 and 13 months of age structured telephone interviews and clinical examinations of the children were conducted. In a subgroup of children blood samples were drawn and stool samples collected at age 4 days, 3 and 13 months. Thymus index was assessed by ultrasound in a subgroup at randomisation and at 3 months. The primary study outcome is hospitalisation within the first 15 months of life as assessed in Danish health registers. Secondary outcomes include infectious disease hospitalisations, wheezing, eczema, use of prescribed medication, growth, development, thymus index, T- and B-cell subpopulations assessed by flow cytometry, in vitro cytokine responses and specific antibody responses to other vaccines. Adverse reactions were registered. With participation of 4184 families and more than 93% adherence to clinical follow-up at 3 and 13 months, this randomised clinical trial has the potential to create evidence regarding non-specific effects of BCG vaccination in a high-income setting.

1 April 2017 in Vaccine
Verified
Journal Article
Open access
TNThomas Nørrelykke Nissen
Thomas Nørrelykke Nissen
NBNina Marie Birk
Nina Marie Birk
GSGaby Smits
Gaby Smits
DJDorthe Lisbeth Jeppesen
Dorthe Lisbeth Jeppesen
LSLone Graff Stensballe
Lone Graff Stensballe
PAPeter Aaby
Peter Aaby
BCG vaccination has been associated with beneficial non-specific effects on child health. Some immunological studies have reported heterologous effects of vaccines on antibody responses to heterologous vaccines. Within a randomised clinical trial of Bacille Calmette-Guérin (BCG) vaccination at birth, The Danish Calmette Study, we investigated the effect of BCG at birth on the antibody response to the three routine vaccines against DiTeKiPol/Act-Hib and Prevenar 13 in a subgroup of participants. Within 7days after birth, children were randomised 1:1 to BCG vaccination or to the control group (no intervention). After three routine vaccinations given at age 3, 5 and 12months, antibodies against DiTeKiPol/Act-Hib and Prevenar 13 (Streptococcus pneumoniae serotype type 4, 6B, 9V, 14, 18C, 19F and 23F) were measured 4weeks after the third vaccine dose. Among the 300 included children (178 BCG; 122 controls), almost all children (>96%) had antibody responses above the protective levels. Overall BCG vaccination at birth did not affect the antibody level. When stratifying by 'age at randomisation' we found a possible inducing effect of BCG on antibodies against B. pertussis and all pneumococcal serotypes, when BCG was given after the first day of life. Girls had significantly higher antibody levels for Haemophilus influenza type b and pneumococcus than boys. Three routine vaccinations with DiTeKiPol/Act-Hib and Prevenar 13 induced sero-protective levels in almost all children. No overall effect of neonatal BCG vaccination was observed.

29 June 2017 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
LTLisbeth Marianne Thøstesen
Lisbeth Marianne Thøstesen
HKHenrik Fomsgaard Kjaer
Henrik Fomsgaard Kjaer
GPGitte Thybo Pihl
Gitte Thybo Pihl
TNThomas Nørrelykke Nissen
Thomas Nørrelykke Nissen
NBNina Marie Birk
Nina Marie Birk
PKPoul Erik Lund Kofoed
Poul Erik Lund Kofoed

1 October 2014 in The Journal of Pediatrics
Verified
Journal Article
Closed access
HEHelle Brander Eriksen
Helle Brander Eriksen
SBSofie Biering-Sørensen
Sofie Biering-Sørensen
NLNajaaraq Lund
Najaaraq Lund
CCCizete Correia
Cizete Correia
ARAmabelia Rodrigues
Amabelia Rodrigues
CBChristine Stabell Benn
Christine Stabell Benn

6 January 2026 in European Heart Journal Open
Verified
Journal Article
Open access
ENEmil H Nørskov
Emil H Nørskov
SSSigne L Skjellerup
Signe L Skjellerup
JNJohan E Navne
Johan E Navne
RRRaheel A Raja
Raheel A Raja
MPMaria M Pærregaard
Maria M Pærregaard
RVR Ottilia B Vøgg
R Ottilia B Vøgg
Aims: Foetal growth restriction (FGR) and being born small for gestational age (SGA) have been linked to later cardiovascular disease. We examined the impact of FGR and SGA on neonatal echo- and electrocardiographic measurements in the Copenhagen Baby Heart Study. Methods and results: The study included 26 175 newborns. Infants with FGR (n = 1020) and SGA (n = 2328) were compared to infants born appropriate for gestational age using linear regression with adjustment for body size, age at examination, sex, and gestational age at birth. FGR and SGA were associated with reduced left ventricular (LV) internal diameters in end-systole [adjusted mean difference (aMD) −0.09 mm, 95% confidence interval (CI) −0.18,0.01, and −0.12 mm, 95% CI −0.19, −0.06, respectively] and end-diastole (aMD −0.13 mm, 95% CI −0.24, −0.02, and −0.15 mm, 95% CI −0.22, −0.07, respectively). Exposed newborns also had thinner LV walls [interventricular septum, end-diastole: FGR −0.07 mm (95% CI: −0.11, −0.03), SGA −0.03 mm (95% CI −0.06, −0.01); LV posterior wall, end-diastole: FGR −0.05 mm (95% CI −0.09, −0.01), SGA −0.04 mm (95% CI −0.07, −0.01)]. Both groups exhibited changes in trans-mitral flow. FGR was associated with reduced right ventricular function (TAPSE aMD −0.20, 95% CI −0.31, −0.09), whereas SGA was associated with reduced LV end-diastolic (aMD −0.16, 95% CI −0.28, −0.04) and end-systolic volumes (aMD −0.08, 95% CI −0.13, −0.02) and alterations in electrocardiogram precordial leads. Both groups demonstrated reduced uncorrected QT intervals. Conclusion: Newborns with FGR or SGA exhibited noteworthy cardiac changes, even after adjustment for body size. Follow-up studies are needed to determine the clinical significance of these findings for the later cardiovascular health. Key Question: Is inadequate foetal growth associated with subclinical changes to the infant heart that can be observed in the newborn using echo- and electrocardiography? Key finding: Foetal growth restriction and being born small for gestational age were associated with reductions in left ventricular thickness and diameter, changes in diastolic function, and alterations in electrocardiographic parameters. Growth-restricted newborns also had altered right ventricular function. Take-home message: Foetal growth restriction and being born small for gestational age are associated with alterations in cardiac structure and function, even after adjustment for body size and age. Follow-up examinations of these children should be considered.